Eva-Lotte Lindstedt-Alstermark

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Astrazeneca Ab, Albireo Ab. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eva-Lotte Lindstedt-Alstermark. Retrieved from https://idiyas.com/inventor/eva-lotte-lindstedt-alstermark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 45.5

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Molndal, SE (2014)
Mölndal, SE (2007 - 2024)

Company Filing History:

Years Active: 2007-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12569489 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2026-03-10),

2. 11975004 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2024-05-07),

3. 11000525 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2021-05-11),

4. 10016430 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2018-07-10),

5. 9616063 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2017-04-11),

6. 9181181 - 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease (2015-11-10),

7. 8785681 - 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease (2014-07-22),

8. 7960380 - Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators (2011-06-14),

9. 7723333 - Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators (2010-05-25),

10. 7429675 - Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid (2008-09-30),

11. 7309720 - 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders (2007-12-18),

Title: Eva-Lotte Lindstedt-Alstermark: Innovator in Cardiovascular Therapy

Introduction

Eva-Lotte Lindstedt-Alstermark is a prominent inventor based in Mölndal, Sweden. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cardiovascular disorders. With a total of 11 patents to her name, her work has the potential to impact many lives.

Latest Patents

One of her latest patents involves the development of 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (MPO). These compounds, along with their pharmaceutically acceptable salts, are designed for therapeutic use. They are particularly useful in treating or preventing cardiovascular disorders such as heart failure and coronary artery disease. The innovative nature of her work lies in the ability of these compounds to inhibit the enzyme MPO, which plays a crucial role in these conditions.

Career Highlights

Throughout her career, Eva-Lotte has worked with notable companies such as AstraZeneca AB and Albireo AB. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Eva-Lotte has collaborated with esteemed colleagues, including Tord Bertil Inghardt and Petra Johannesson. These partnerships have fostered an environment of innovation and have led to the successful development of her patented compounds.

Conclusion

Eva-Lotte Lindstedt-Alstermark is a trailblazer in the field of cardiovascular therapy, with a strong portfolio of patents that reflect her dedication to improving health outcomes. Her innovative work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.